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Background and purpose: Therapeutic drug monitoring is a valuable tool supporting im-
munosuppressive therapy. Significant variation of immunosuppressive drug (ISD) concen-
trations during their use at similar doses is the basis of dose-normalization strategy. The
strategy of dose-adjustment is proposed to identify variability in the rate of ISD metabolism.
While the parent drug-to-metabolite ratio (metabolic ratio, MR) represents the rate of for-
mation of individual metabolites. The present study was aimed at evaluation of associa-
tions between ISDs’ metabolism rate expressed as dose-adjusted concentrations (C/D) and
dose/kg-adjusted concentrations (C/D/kg) and MRs of individual metabolites of tacrolimus,
cyclosporine A and MPA precursors.
Experimental approach: 506 patients have participated: 284 males (56.13%) and 222 fe-
males (43.87%); 318 after kidney (62.85%) and 188 after liver transplantation; median age
was 51.34 (39.32-59.95) years and median time after transplantation 78.92 (33.87-138.4)
months.
Key results: Generally, we have not observed significant relationships between
dose-adjusted and dose/kg-adjusted concentrations and MRs of cyclosporine and
tacrolimus. Significant correlations were found for: AM9/CsA and dMC-CsA/CsA in kidney
transplant recipients and MIII/Tac, AM1/CsA and AM4N/CsA in liver transplant recipients.
In contrast, MRs of mycophenolic acid (MPA) metabolites correlated significantly with MPA
C/D and C/D/kg both in kidney and liver transplant recipients.
Conclusion and implications: In conclusion, easily available and easy to use in clinical prac-
tice C/D and C/D/kg ratios cannot be considered as parameters directly reflecting the rate
of generation of major metabolites of cyclosporine and tacrolimus both in liver and kidney
transplant recipients.
Introduction
Therapeutic drug monitoring (TDM) is a valuable tool that supports usage of medicinal products with
narrow therapeutic window and high inter- and intraindividual variability of dose/exposure relationship.
Due to considerable potency of adverse and toxic effects, immunosuppressive therapy after solid organ
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transplantation requires application of TDM. Traditionally, immune tests are used for TDM, however, chromatogra-
phy with mass spectrometry is considered the most accurate method [1].
As a natural consequence of phases I and II of drugs biodegradation, various metabolites of immunosuppres-
sive drugs (ISD) become detectable in the blood and tissues. Some of these metabolites are toxic and may ex-
hibit some immunosuppressive activity, but our knowledge in this field is limited. Cyclosporine A (CsA) is me-
tabolizsed in the I phase due to CYP3A4 and CYP3A5 activity and its major metabolites are AM1, AM9 and
AM4N [2]. Those three metabolites also exhibit the highest biological activity of the parent drug. Metabolism
of tacrolimus (Tac) is mainly hepatic by P450 enzyme system: CYP3A4 that forms mainly 15-O-desmethyl-Tac
(MIII) and smaller amounts of 13-O-desmethyl-Tac (MI) and 31-O-desmethyl-Tac (MII), and CYP3A5 that forms
mainly 31-O-desmethyl-Tac and smaller amounts of 13-O-desmethyl-Tac, 15-O-desmethyl-Tac and 12-hydroxy-Tac
(MIV). Mycophenolic acid (MPA) is the active metabolite of two commercially available mycophenolates (my-
cophenolic acid precursors (pMPA)) formed by its rapid hydrolysis. Mycophenolic acid metabolism in hepato-
cytes, enterocytes and renal cells leads to formation of its metabolites: 6-O-desmethyl-MPA, 7-O-MPA-glucuronide,
phenyl-MPA-glucuronide (MPAG), acyl-MPA-glucuronide (AcMPAG) and 7-MPA-glucoside (GluMPA). MPAG is
considered the major inactive MPA metabolite and reaches plasma concentrations approximately 20- to 100-fold
higher than parent drug [3]. The awareness of the influence of genetic variability and of many other factors on
the rate of ISD metabolism has become a reason to look for appropriate indicators. Significant variation of im-
munosuppressive drug concentrations during their use at similar doses was the basis of dose-normalization strategy.
Dose-normalization was applied both to the parent drug concentrations and to metabolites’ concentrations [4–8].
Higher drug concentration/dose ratios are indicative of lower activity of complex processes leading to ISD clearance
from patients’ blood, including slower metabolism, whereas higher metabolite concentration/dose ratios indicate in-
creased rate of these processes. Calculation of metabolic ratio (MR) represents another strategy that evaluates more
closely the intensity of parent drugmetabolism. No uniform strategy has been developed and various authors propose
different approaches, i.e. calculation of individualmetabolite to parent drug concentration ratio, individualmetabolite
AUC to parent drug AUC ratio, and total metabolites concentration to parent drug concentration ratio [8–14].
In order to conduct a more detailed assessment of the proposed strategies, the present study was aimed at evalu-
ation of associations between immunosuppressive agents’ clearance rate expressed as dose-adjusted concentrations
(C/D) and dose/kg-adjusted concentrations (C/D/kg) and metabolic ratios of individual metabolites of tacrolimus,
cyclosporine A and MPA precursors in patients after kidney transplantation (KTX) or liver transplantation (LTX).
Experimental
The study was performed in the outpatient clinic of the Department of Immunology, Transplant Medicine, and In-
ternal Diseases of the Medical University of Warsaw (MUW) from May 2014 to April 2016. The study protocol was
approved by theMUWEthical Committee. Before the study procedures, all patients have given their written informed
consent. All procedures performed were in accordance with the ethical standards of the MUW Ethical Committee
and with the 1964 Helsinki declaration and its later amendments.
The study included all patients who presented to our transplant clinic for routine planned visit, who were on stable
immunosuppression therapy for at least 3 months, who have no acute health problems, and who have given their
informed consent to participate in the study. From each study participant 2 ml of blood was collected during the
routine outpatient visit. The blood samples were withdrawn 12 h after administration of the last ISD dose. The time
interval was controlled by experienced transplant nurse staff on the basis of patients’ declarations.
Whole blood concentration of cyclosporine and its metabolites: AM1, AM9, dihydro-cyclosporine (DiH-CsA),
trihydro-cyclosporine (TriH-CsA) and desmethylcarboxy-cyclosporine (dMC-CsA); tacrolimus and its metabolites:
13-O-desmethyl tacrolimus (MI), 15-O-desmethyl tacrolimus (MIII); and plasma concentrations of mycophenolic
acid (MPA) and its metabolites: phenyl glucuronide (MPAG), acyl glucuronide (AcMPAG) and glucoside (GluMPA)
were quantified at the Institute of Biochemistry and Biophysics using liquid chromatography-tandem mass spec-
trometry method (LC-MS/MS). Analyses were performed using Waters Acquity Ultra Performance Liquid Chro-
matograph coupled with Waters TQ-S triple-quadrupole mass spectrometer (Waters Corporation, Milford, US), as
described previously [19].
Clinical and laboratory data were extracted from patients’ medical records and included in dedicated database.
Data concerning patients’ body mass and ISD daily dose were extracted from patients’ medical records.
Dose-adjusted ISD concentrations and dose/kg-adjusted ISD concentrations were calculated using the following
equations: ISD concentration (ng/ml)/ISD daily dose (mg/day) or (g/day) and ISD concentration (ng/ml)/ISD daily
2 © 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
License 4.0 (CC BY).
Bioscience Reports (2019) 39 BSR20182031
https://doi.org/10.1042/BSR20182031
Figure 1. Relationship between dose-adjusted and dose/kg-adjusted tacrolimus concentrations and metabolic ratios of
tacrolimus metabolites MI, MIII and MI+MIII
(A and B) Lack of correlations between tacrolimus C/D and C/D/kg and metabolic ratios of MI, MIII and MI+MIII. (C and D)
C/D, dose-adjusted concentration; C/D/kg, dose/kg-adjusted concentration; ISD, immunosuppressive drug; Tac, tacrolimus; MI,
13-O-desmethyl tacrolimus; MIII, 15-O-desmethyl tacrolimus; KTX, kidney transplant.
dose per body mass kilogram (mg/kg/day) or (g/kg/day), respectively. The individual ISD metabolites’ metabolic ra-
tios (MR)were calculated using the following equation: (metabolite concentration (ng/ml)/parent drug concentration
(ng/ml))× 100%. Total concentrations and concentrations of the given immunosuppressive drug were calculated us-
ing the following equations: AM1 + AM9 + AM4N for cyclosporine A, MI + MIII for tacrolimus and GluMPA +
AcMPAG +MPAG for MPA.
Data and statistical analysis: All calculations were performed using Statistica 13.1 (Dell, Texas, USA). We used the
Shapiro–Wilk test to assess the type of distribution of analysed variables. Not-normally distributed variables were
presented as median and interquartile range (IQR) and were analysed using Spearman’s correlation coefficient. KTX
and LTX populations were analysed separately. The differences were considered statistically significant when P <
0.05.
Results
A total of 506 patients have participated in the study: 284 males (56.13%) and 222 females (43.87%); 318 patients
were kidney recipients (62.85%) and 188 patients were liver recipients (37.15%); steroids were taken by 369 patients
(72.93%); pMPAwere taken by 314 patients (62.06%); Tac was taken by 308 patients (60.87%) and CsA was taken 157
patients (31.03%). Median age with interquartile range was 51.34 (39.32–59.95) years, median time after transplan-
tation with interquartile range was 78.92 (33.87–138.4) months.
Due to the number of medicines taken and the small group sizes for individual concomitant drugs, ISD and trans-
planted organs, it was not possible to analyse the relationship between individual drug groups and the parame-
ters of ISD and their metabolites. However, analysed patients did not take many agents listed in the summary of
products’ characteristics as entering the most relevant and best documented interactions, i.e. barbiturates, carba-
mazepine, oxcarbamazepine, phenytoin, nafcillin, intravenous sulfadimidine, probucol, orlistat, ticlopidine, sulfin-
pyrazone, terbinafine, bosentan, rifampicin, octreotide,metoclopramide, high doses ofmethylprednisolone, imatinib,
colchicine, nicardipine and nefazodone. The most numerous groups of drugs taken by the patients were medicines
used in the treatment of hypertension, coronary heart disease, dyslipidaemia and hyperglycaemia: loop diuretics
(29.96%), thiazide diuretics (6.1%), spironolactone (5.15%), angiotensin convertase inhibitors (17.46%), angiotensin
receptor blockers (6.99%), alpha-adrenergic blockers (13.95%), beta-adrenergic blockers (52.02%), calcium chan-
nel blockers (31.25%), imidazoline receptor agonists (7.9%), insulin (15.26%), oral antidiabetic drugs (5.33%) and
HMG-CoA reductase inhibitors (33.82%).
Generally, we have not observed significant relationships between dose-adjusted and dose/kg-adjusted concen-
trations and MRs of cyclosporine and tacrolimus (Figure 1). There were some exceptions, i.e.: AM9/CsA and
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Table 1 Spearmans’ correlations between tacrolimus, cyclosporine A and MPA precursors’ dose-adjusted and





r P r p
Tac C/D (ng/ml/mg) MI/Tac −0.1 0.26 0.12 0.22
MIII/Tac −0.06 0.5 −0.25 0.02
MI+MIII/Tac −0.13 0.16 0.05 0.64
Tac C/D/kg (ng/ml/mg/kg) MI/Tac −0.06 0.51 0.1 0.35
MIII/Tac −0.08 0.36 −0.26 0.01
MI+MIII/Tac −0.09 0.32 0.02 0.88
CsA C/D (ng/ml/mg) AM1/CsA 0.01 0.95 −0.32 0.12
AM9/CsA −0.31 0.01 −0.38 0.07
AM4N/CsA −0.03 0.81 0.02 0.93
DiH-CsA/CsA 0.09 0.48 −0.18 0.39
TriH-CsA/CsA 0.1 0.47 −0.37 0.15
dMC-CsA/CsA −0.3 0.19 −0.02 0.96
AM1+AM9+AM4N/CsA −0.03 0.82 −0.35 0.1
CsA C/D/kg (ng/ml/mg/kg) AM1/CsA −0.18 0.16 −0.41 0.049
AM9/CsA −0.12 0.34 −0.25 0.23
AM4N/CsA 0.14 0.29 0.46 0.034
DiH-CsA/CsA 0.04 0.75 0.04 0.87
TriH-CsA/CsA 0.01 0.93 0.18 0.49
dMC-CsA/CsA −0.5 0.03 0.26 0.53
AM1+AM9+AM4N/CsA −0.18 0.16 −0.38 0.07
MPA C/D (ng/ml/g) MPAG/MPA −0.69 0.000001 −0.7 0.000001
AcMPAG/MPA −0.39 0.000001 −0.44 0.0009
GluMPA/MPA −0.43 0.000001 −0.41 0.001
GluMPA+AcMPAG+MPAG/MPA
−0.69 0.000001 −0.7 0.000001
MPA C/D/kg (ng/ml/g/kg) MPAG/MPA −0.66 0.000001 −0.59 0.000001
AcMPAG/MPA −0.37 0.000001 −0.32 0.02
GluMPA/MPA −0.39 0.000001 −0.39 0.002
GluMPA+AcMPAG+MPAG/MPA
−0.65 0.000001 −0.59 0.000001
C/D, dose-adjusted concentration; C/D/kg, dose/kg-adjusted concentration; Tac, tacrolimus; CsA, cyclosporine A; MPA, mycophenolic acid; ISD,
immunosuppressive drug; AM1, 1-hydroxy cyclosporine; AM9, 9- hydroxy cyclosporine; AM4N, 4-N-demethyl cyclosporine; dMC-CsA, demethyl-
carboxylated cyclosporine metabolites; DiH-CsA, dihydroxylated cyclosporine metabolites; TriH-CsA, trihydroxylated cyclosporine metabolites; MI,
13-O-desmethyl tacrolimus; MIII, 15-O-desmethyl tacrolimus; MPA, mycophenolic acid; MPAG, phenyl glucuronide; AcMPAG, acyl glucuronide; GluMPA,
glucoside
dMC-CsA/CsA in kidney transplant recipients and MIII/Tac, AM1/CsA and AM4N/CsA in liver transplant recip-
ients (Table 1 and Figure 2A,B). In contrast, different results were obtained in the case of MPA. We have observed
strong relationships for both MPA C/D and C/D/kg and all MR values (GluMPA, AcMPAG, MPAG and total MPA
metabolites’ concentration; Table 1 and Figure 3A,B).
Discussion
Observations revealing significant variation of immunoassays results evaluating concentrations of immunosuppres-
sive drugs and variations of metabolites’ concentrations at the same parent drug concentrations are the reason for the
need to seek new strategies of TDM. It has not yet been established with certainty whether and which ISDmetabolites
are relevant for the solid organ transplantation outcomes. There are some studies suggesting that they may be clini-
cally significant [8,15,16]. Since the determination of concentrations of individual ISDmetabolites or polymorphisms
of genes encoding enzymes engaged in the metabolism of immunosuppressants are not widely available, C/D and
C/D/kg evaluation seems to be a very promising strategy [6,7]. It is hypothesized that C/D and C/D/kg ratios reflect
the immunosuppressive drug metabolism rate and hence the overall activity of enzymatic metabolic systems. With
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Figure 2. Relationship between dose-adjusted and dose/kg-adjusted cyclosporine A concentrations and metabolic ratios
of cyclosporine A metabolites AM1, AM9, AM4N, dMC-CsA, dihydroxylated-CsA and trihydroxylated-CsA
(A and B) Lack of correlations between cyclosporine C/D and C/D/kg and metabolic ratios of AM1, AM9, AM4N, DiH-CsA, Tri-
H-CsA, dMC-CsA and AM1+AM9+AM4N. CsA, cyclosporine A; ISD, immunosuppressive drug; AM1, 1-hydroxy cyclosporine; AM9,
9-hydroxy cyclosporine; AM4N, 4-N-demethyl cyclosporine; dMC-CsA, demethylcarboxylated cyclosporine metabolites; DiH-CsA,
dihydroxylated cyclosporine metabolites; TriH-CsA, trihydroxylated cyclosporine metabolites; KTX, kidney transplant.
Figure 3. Relationship between dose-adjusted and dose/kg-adjusted MPA concentrations and metabolic ratios of MPA
metabolites GluMPA, MPAG and AcMPAG
(A and B) Statistically significant correlation between MPA C/D and C/D/kg and metabolic ratios of GluMPA, AcMPAG and MPAG.
MPA, mycophenolic acid; ISD, immunosuppressive drug; MPA, mycophenolic acid; MPAG, phenyl glucuronide; AcMPAG, acyl
glucuronide; GluMPA, glucoside; KTX, kidney transplant.
this assumption, one would expect that the higher dose-adjusted concentrations will be accompanied by lower pro-
duction of individual metabolites and therefore lower MRs. However, we found that for tacrolimus and cyclosporine
such relationships are not present in general. A completely different situation concernsMPA precursors. One possible
explanation is the fact that the rate of formation of individual ISD metabolites and parent drug clearance depend not
only on the activity of enzymes, but also on the activity of transport systems, mainly multidrug resistance 1 protein
(MRP1) and multidrug resistance related protein (MRP) family. The different results in the case of pMPA may re-
sult from a significant impact on the analysed parameters of high concentrations of MPAG and different enzymatic,
non-enzymatic and transport pathways involved in the pMPA pharmacokinetics.
It is suggested that faster metabolism in kidney transplant recipients receiving tacrolimus is associated with worse
kidney graft function, worse prognosis and shorter graft survival [7]. Our research indicate that this is probably not
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directly associated with the presence of the major tacrolimus metabolites, i.e. MI and MIII. Similar conclusions can
be drawn in regard to cyclosporine. Interestingly, in the case of pMPA, there is a direct link between C/D and C/D/kg
ratios and concentrations of major MPAmetabolites: GluMPA, AcMPAG andMPAG. Certainly, this requires further
research considering the genetic variability of enzymes and transport proteins involved in the pharmacokinetics of
immunosuppressants. It is suggested that MRs can be used as a surrogate of activity of cytochrome P450 isoenzymes
indicating the presence of their specific polymorphisms [4,17]. Other authors indicate that a much more accessible
parameters, such as C/D and C/D/kg ratios, can be used for this purpose [6]. In our study, we have showed that such
strategy may probably be applied in the case of MPA precursors, but not in the case of cyclosporine nor tacrolimus.
The research concerning the activity of enzyme and transport proteins involved in the pharmacokinetics of ISDs un-
derlines the differences resulting from the presence of the transplanted organ: kidney or liver. The lack of relationship
that was found in regard to CsA and Tac and the existence of correlations in the case of MPAwere independent of the
type of organ transplanted. The question of the influence of the ISD concentrations assessment methods on the ob-
tained results also needs to be clarified, asmany studies analysing dose-adjusted concentrations and pharmacogenetic
studies used immunoassays [7,18].
In conclusion, easily available and easy to use in clinical practice C/D and C/D/kg ratios cannot be considered as
parameters directly reflecting the rate of generation of major metabolites of cyclosporine and tacrolimus both in liver
and kidney transplant recipients.
Perspectives
Immunosuppressants’ dose-adjusted concentrations are proposed as measure of metabolism of
parent drugs. This study was aimed at clarifying whether dose-adjusted and dose/kg-adjusted drug
concentrations can be used as a measure of the generation of individual metabolites of tacrolimus,
cyclosporine and mycophenolic acid.
• We have observed lack of correlation between dose-adjusted tacrolimus and cyclosporine concen-
trations and levels of metabolites; and high correlation for mycophenolic acid.
• Potential significance of the results.
• Tacrolimus and cyclosporine dose-adjusted concentrations cannot be used as surrogate of
metabolites’ generation.
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